The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review

Supportive Care in Cancer

Volumn 24, Issue 8, 2016, Pages 3669-3676

  Atkinson, Thomas M ^a   Ryan, Sean J ^a,b   Bennett, Antonia V ^c   Stover, Angela M ^c   Saracino, Rebecca M ^a   Rogak, Lauren J ^a   Jewell, Sarah T ^d   Matsoukas, Konstantina ^a   Li, Yuelin ^a   Basch, Ethan ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Drug monitoring; Drug related side effects and adverse reactions; Literature review; Neoplasms; Self report; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ANUS CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICIAN BASED COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; DRUG MONITORING; DYSPNEA; ENDOMETRIUM CANCER; ERECTILE DYSFUNCTION; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HUMAN; LUNG CANCER; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PATIENT REPORTED OUTCOMES; PELVIS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VOMITING; DRUG SURVEILLANCE PROGRAM; FEMALE; PATIENT-REPORTED OUTCOME; PROCEDURES; STANDARDS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; PATIENT REPORTED OUTCOME MEASURES; SELF REPORT;

EID: 84975847327     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3297-9     Document Type: Review

References (41)

1. Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869
2. Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307–317
3. Vyzula RRS (1996) Lung cancer in patients with HIV-infection. Lung Cancer 15:325–339
4. Basch E, Reeve BB, Mitchell SA, et al. (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244
5. Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15:401–403
6. Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127
7. US Department of Health and Human Services (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 5 Jan 2016
8. Hay JL, Atkinson TM, Reeve BB, et al. (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23:257–269
9. Dueck AC, Mendoza TR, Mitchell SA, et al. (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059
10. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384
11. Mandala M, Cremonesi M, Rocca A, et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 13:375–380
12. Alberti P, Rossi E, Cornblath DR, et al. (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264
13. Brabo EP, Paschoal ME, Biasoli I, et al. (2006) Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res 15:1519–1524
14. Christodoulou M, McCloskey P, Stones N, et al. (2014) Investigation of a patient reported outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 112:244–249
15. Di Maio M, Gallo C, Leighl NB, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915
16. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490
17. Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2011) Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19:1421–1427
18. Jensen K, Lambertsen K, Torkov P, et al. (2007) Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol 46:1159–1168
19. Kirchheiner K, Nout R, Lindegaard J, et al. (2012) Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol: Organ der Deutschen Rontgengesellschaft [et al] 188:933–939
20. Quinten C, Maringwa J, Gotay CC, et al. (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851–1858
21. Cella D, Huang H, Homesley HD, et al. (2010a) Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 119:538–542
22. Hirsh V, Okamoto I, Hon JK, et al. (2014) Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thoracic Oncol Off Publ int Assoc Study Lung Cancer 9:83–90
23. Shimozuma K, Ohashi Y, Takeuchi A, et al. (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17:1483–1491
24. Atherton PJ, Burger KN, Loprinzi CL, et al. (2012) Using the Skindex-16 and common terminology criteria for adverse events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer 20:1729–1735
25. Neben-Wittich MA, Atherton PJ, Schwartz DJ, et al. (2011) Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397–402
26. Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632
27. Efficace F, Rosti G, Aaronson N, et al. (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788–793
28. Flores LT, Bennett AV, Law EB, et al. (2012) Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res GCR 5:119–124
29. Tom A, Bennett A, Rothenstein D, et al. (2013) Prevalence of patient-reported gastrointestinal symptoms and concordance with clinician toxicity assessments in radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 87:S570–S571
30. Basch E, Iasonos A, McDonough T, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909
31. Cirillo M, Venturini M, Ciccarelli L, et al. (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935
32. Gravis G, Marino P, Joly F, et al. (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953–962
33. Cella D, Pulliam J, Fuchs H, et al. (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412
34. Steinsvik EA, Fossa SD, Axcrona K, et al. (2010) Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 184:525–531
35. Franklin HR, Simonetti GP, Dubbelman AC, et al. (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5:113–117
36. Cella D, Riley W, Stone A, et al. (2010b) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 63:1179–1194
37. Bennett BK, Park SB, Lin CS, et al. (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20:2959–2967
38. Tang B, Giuliani M, Le LW, et al. (2013) Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. Clin Lung Cancer 14:108–112
39. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355–1363
40. Atkinson TM, Li Y, Coffey CW, et al. (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164
41. Park JH, Kim YS, Park J, et al. (2014) Incidence and dose-volume analysis of acute bladder toxicity following pelvic radiotherapy. Tumori 100:195–200